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Abstract 
Non-motor symptoms (NMS) are integral to Parkinson’s disease (PD) and the 
management can often be challenging. In spite of the growing evidence that NMS 
have a key impact on the quality of life of patients and caregivers, most clinical trials 
still focus on motor symptoms as primary outcomes. As a consequence strong 
evidence based treatment recommendations for NMS occurring in PD are spare. In 
this chapter we describe the current data addressing the treatment of major NMS such 
as sleep, cognitive and autonomic dysfunction, depression and anxiety.  
 
Introduction 
Non-motor symptoms (NMS) are integral to the course of Parkinson’s disease (PD) 
(Sauerbier and Ray Chaudhuri, 2014) and being one of the key factors for the quality 
of life of both patients and caregivers, NMS play a major role in the management of 
this neurodegenerative condition (Martinez-Martin, 2014). Since 2006, objective 
measurements of NMS with validated tools (questionnaires and scales) have been 
developed, which are now in widespread use in standard clinical care and clinical 
trials. The two main NMS tools are the patient completed NMS Questionnaire (NMS 
Quest) and health-professional completed NMS Scale (NMSS) (Chaudhuri et al., 
2006b, Chaudhuri et al., 2007, Chaudhuri et al., 2006a). In addition, NMS can also be 
measured, although in a limited fashion, by the NMS section of the Movement 
Disorders Society- Unified Parkinson’ disease rating scale (MDS-UPDRS) (Goetz et 
al., 2008). Figure 1 summarizes a proposed pathway that might help to assess and 
manage NMS in clinical practice. 
In this chapter we review published clinical trials addressing the treatment of NMS in 
PD with a particular focus on trials using the NMS Quest and NMSS, which have the 
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most widely published clinometric data. Major NMS, including sleep, cognitive and 
autonomic dysfunction as well as depression and anxiety, will be described in detail. 
 
 
Figure 1: Proposed pathway to assess NMS holistic in clinical practice and 
consider further management 
MDT = Multi-disciplinary-team; NMS = Non-motor symptoms; MDS-UPDRS = 
Movement Disorders Society- Unified Parkinson’s disease rating scale 
(Ray Chaudhuri et al, 2015; Sauerbier et al, 2016) 
 
 
Sleep  	
Sleep disturbances are common in PD and consist mainly of night-time sleep 
difficulties such as insomnia, rapid eye movement (REM) sleep behavior disorder 
(RBD), restless legs syndrome (RLS), periodic limb movement disorder (PLM), and 
sleep disordered breathing, but also of excessive daytime sleepiness (EDS) and early 
morning ‘off’ (Chahine et al., 2016). In clinical practice, apart from the NMS Quest 
and NMSS, more specific tools, such as the Parkinson’s disease Sleep Scale version 1 
and 2 (PDSS and PDSS-2) (Chaudhuri et al., 2007, Trenkwalder et al., 2011b) and the 
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Epworth Sleepiness Scale (ESS) (Johns, 1991, Hagell and Broman, 2007), are 
available to investigate sleep disturbances in the bedside.  
Despite the overwhelming importance, only few randomized controlled trials and high 
quality open-label studies have approached the management of sleep disturbance in 
PD (Chahine et al., 2016, Schrag et al., 2015, Rodrigues et al., 2016).  
As first line interventions, general sleep hygiene recommendations cannot be 
overemphasized, and the potential effects of dopaminergic therapy on sleep 
investigated. It has been recognized that some sleep symptoms can be worsened by 
dopaminergic therapy, as seen with EDS for example, possibly due to the action of 
dopamine D3 agonists, as has been suggested in the proposed Park Sleep subtype 
(Sauerbier et al., 2016).  
On the other hand, sleep fragmentation can be partly explained by night-time motor 
fluctuations. and RLS. Continuous drug delivery, as well as controlled-release 
formulations of levodopa or dopamine agonists, transdermal delivery of rotigotine, 
and addition of inhibitors of catechol-O-methyltransferase or monoamine oxidase-B 
can be effective improving nocturnal motor disability, fluctuation as well as early 
morning ‘off’. Aforesaid observations have been previously reported with cabergoline 
(Romigi et al., 2006, Marco et al., 2002). A recent open-label, multicenter study has 
shown a positive effect of rasagiline as mono- or add-on therapy on sleep disturbances 
as assessed by PDSS (Panisset et al., 2016).	Additionally, rotigotine transdermal 
patches have shown to ameliorate sleep dysfunction in PD in randomized trials. The 
multicenter, randomized, double-blind, placebo-controlled ‘RECOVER’ trial 
investigated the effect of the rotigotine transdermal patch on sleep dysfunction and 
showed a significant improvement in nocturnal sleep disturbances as assessed by 
PDSS-2 and NMSS (Trenkwalder et al., 2011a). These results are in line with 
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findings of open-label studies and a randomized trial using subjective clinical scales 
and objective recordings, including polysomnography (Pagonabarraga et al., 2015, 
Calandra-Buonaura et al., 2016, Pierantozzi et al., 2016).  Furthermore, the 
‘RECOVER’ study reported a low incidence of EDS as an adverse event 
(Trenkwalder et al., 2011a). It has been hypothesized that this might be at least partly 
explained by the fact that rotigotine does not share the high affinity D3 receptor 
profile of other dopamine agonists (Sauerbier et al., 2016, Chaudhuri and Sauerbier, 
2016). 
Beneficial effects have been observed with PD advanced therapies in open-label 
studies as well. Results from a surveillance-based study on apomorphine showed a 
significant improvement in the domain of sleep/fatigue of NMSS at follow up, of 
particular importance in individual items assessing fatigue, sleep-onset insomnia and 
RLS (Martinez-Martin et al., 2011). The open-label, prospective, observational, 
multicenter ‘Euroinf’ study compared patients on apomorphine infusion to patients on 
intrajejunal levodopa infusion (IJLI) which demonstrated a significantly higher 
improvement in NMSS sleep domain for those on IJLI (Martinez-Martin et al., 2015). 
Zibetti et al  also noted improvement in subjective sleep quality and EDS as assessed 
by PDSS-2 and ESS in patients treated with IJLI (Zibetti et al., 2013).  
Significant improvement has been described after bilateral subthalamic stimulation 
measured by NMSS sleep domain and PDSS (Dafsari et al., 2016). Furthermore, 
similar results have been achieved after microsubthalamotomy in a small sample of 
15 patients (Merlino et al., 2014). However, a recent systematic review on deep brain 
stimulation (DBS) and sleep-wake functions in PD has summarized that the current 
literature is conflicting and more work is needed in this field (Eugster et al., 2016).   
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When further pharmacological intervention is warranted to treat insomnia, 
antidepressants (including tricyclics, trazodone, agomelatine), non-benzodiazepine 
hypnotics (including eszopiclone) as well as melatonin (5 mg/day) can be tried (Rios 
Romenets et al., 2013, Seppi et al., 2011, Dowling et al., 2005). Doxepin, a tricyclic 
antidepressant with selective histaminergic antagonistic action, has been reported to 
be effective at low dosages (10 mg/day nocte) (Rios Romenets et al., 2013). 
Additionally, it is important to consider the sleep environment and ensure that RBD 
sleep-related injury is prevented (Chahine et al., 2016). Melatonin and clonazepam 
are prescribed routinely to control RBD, with the former showing a more favorable 
adverse event profile in patients with concomitant sleep disordered breathing (Aurora 
et al., 2010). A randomized, double-blind, placebo-controlled trial investigated the 
effects of rivastigmine transdermal patch (4.6 mg/day) in a small sample of PD 
patients with severe RBD (>5 episodes/week) refractory to clonazepam (2 mg/day) 
and melatonin (5 mg/day). Rivastigmine was found to significantly decrease the 
number of RBD episodes at 3-week follow up (Di Giacopo et al., 2012).  
RLS in PD is currently not yet fully understood and there are currently no randomized 
controlled trials addressing the different therapies to improve RLS specifically 
occurring in PD. Generally, iron deficiency should be excluded as a cause of RLS in 
PD. Studies investigating the effect of DBS have reported conflicting findings. 
(Chahine et al., 2016). 
EDS should be primarily addressed by reducing potentially causative medications. 
Combined analysis of 3 randomized, double-blind, placebo-controlled trials support 
the evidence that modafinil (100-200 mg/day) taken in the morning improves EDS in 
PD patients (Rodrigues et al., 2016). Other stimulants such as caffeine and 
methylphenidate have been investigated as well, however, these therapies remain 
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investigational (Postuma et al., 2012, Chahine et al., 2016). Sodium oxybate at night-
time has also been suggested for the treatment of EDS (with caution because of 
addictive potential) and further studies are currently investigating this effect (Ondo et 
al., 2008). One study has shown that when continuous positive airway pressure 
(CPAP) is used to treat sleep apnea, it has an additional positive effect on EDS as well 
(Neikrug et al., 2014). 
Apart from pharmacological therapies, some non-pharmacological interventions have 
observed interesting positive results, such as a multidisciplinary intensive 
rehabilitation treatment (Frazzitta et al., 2015) and bright light therapy (Rutten et al., 
2012). However, such treatments are not readily available worldwide. 
 
In conclusion, management of sleep dysfunction is complex and needs accurate 
diagnosis of the specific type of disturbance, which can be achieved with clinical 
tools such as the PDSS. Therapy should then be tailored according to specific issues 
such; as early morning ‘off’, nocturnal motor symptoms, sleep fragmentation, RLS 
and RBD. Apart from the few but increasing number of studies addressing sleep 
disturbances in PD, strong recommendations cannot be made at this point. 
 
Cognition 	
Cognitive impairment is a common NMS in PD (Broeders et al., 2013). Initial deficits 
presenting as mild cognitive impairment (MCI) can be detected in 15% of patients at 
the time of diagnosis (Aarsland and Kramberger, 2015). Those may remain stable or 
progress to PD dementia (PDD) over time. Only a few systematic studies are 
currently available which addressed the treatment of cognitive impairment 
specifically in PD. In a recent systematic review physical activity was shown to 
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positively impact cognition in PD (Cusso et al., 2016). The effect of drug therapy on 
MCI is currently controversial (Strohle et al., 2015). Arecent study highlighted that 
application of anodal transcranial direct current stimulation could improve cognitive 
abilities in MCI PD (Manenti et al., 2016). 
Treatment of PDD in clinical practice can involve the use of cholinergic agents.  
Rivastigmine has been shown to be efficacious in large, randomized placebo 
controlled trials (Seppi et al., 2011). On the other hand, open-label and randomized 
controlled studies also suggested that donepezil can improve cognition in PD, but the 
results are inconclusive and as such no general recommendations could be made. 
(Cooney et al, 2016). Galantamine has only been evaluated for PDD in open label 
studies and evidence is currently insufficient to recommend Galantamine for the 
treatment of PDD (Seppi et al., 2011). A recent systematic meta-analysis suggested 
that memantine, a low-affinity antagonist to glutamate NMDA receptors, possibly 
shows a slight improvement in global impression of cognitive dysfunctions in PD 
(Wang et al., 2015) . 
 Moreover, a small, open label, pilot study of atomoxetine for cognitive impairment 
found an improvement in executive functions measures (Marsh et al., 2009). 
In conclusion, cognitive dysfunction may occur in PD even at early stages, now 
recognized as Park Cognitive subtype (Sauerbier et al., 2016). Cognitive dysfunction 
is one of the key problems in advanced PD and reasonable evidence base exists with 
cholinergic agents in PD. However, further research needs to be conducted. 
 
 
 
Depressive symptoms and anxiety 
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The prevalence of depression and anxiety disorders in PD varies considerably across 
different settings and the screening tools used. Recently published systematic reviews 
estimate a prevalence for both, major and minor depression, and any anxiety disorder, 
to be around 30% (Goodarzi et al., 2016, Broen et al., 2016). 
 
Behavioral and psychosocial interventions in PD patients have been shown to have a 
beneficial effect particularly during the acute management of depression and anxiety, 
while longer term effects are still unclear (Yang et al., 2012). In this context, 
cognitive behavioral therapy (CBT), with some studies looking at telephone-
administered CBT, has shown promising results (Armento et al., 2012, Bomasang-
Layno et al., 2015). Bright light therapy has been suggested as beneficial for 
depressive symptoms in PD, possibly through restoring the circadian rhythm which 
maybe involved in the development of depressive symptoms (Rutten et al., 2012). A 
recent systematic review has highlighted the potential positive impact of physical 
activity on NMS such as depression, however further studies are needed to confirm 
this (Cusso et al., 2016). The first treatment with electroconvulsive therapy (ECT) for 
psychiatric and neurological disorders goes back to 1947 (Moellentine et al., 1998, 
Narang et al., 2015). The usefulness of ECT in PD has been recently outlined with a 
positive effect being described on depressive symptoms, however more prospective, 
controlled studies are needed in this field to evaluate if ECT should be considered 
earlier (Borisovskaya et al., 2016). 
 
Regarding pharmacological interventions, it is important to establish if depressive 
symptoms and anxiety are related to non-motor fluctuations in which case adjustment 
of dopaminergic medication should be considered.  
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Furthermore, serotonin–norepinephrine reuptake inhibitors (SNRIs) such as 
mirtazapine and venlafaxine as well as serotonin selective reuptake inhibitors (SSRIs) 
such as fluoxetine, sertraline, citalopram and paroxetine are among the commonly 
used treatments for depressive symptoms and anxiety in PD. Moreover, tricyclic 
antidepressants (TCAs) including amitriptyline and nortriptyline are commonly used 
in clinical practice as well. Even though the published literature is conflicting, in 
general SSRIs remain the first treatment of choice (Pena et al., 2016). 
 
There is now also good evidence that several dopaminergic drugs are useful to treat 
depressive symptoms in PD. Pramipexole, a dopamine agonist, has been shown to be 
efficacious for the treatment of depressive symptoms in PD (Barone et al., 2010). The 
‘RECOVER’	study showed an improvement in depressive symptoms assessed by the Beck	Depression	Inventory	(BDI-II) and NMSS with rotigotine (Trenkwalder et al., 
2011a). Furthermore, a prospective open-label multicenter study investigating the 
effect of ropinirole over 6-months, showed a significant improvement in depressive 
symptoms and anxiety measured by the Hamilton Anxiety Scale (HAM-A) and 
Montgomery-Asberg Depression Rating Scale (MADRS) in patients with motor 
fluctuations (Rektorova et al., 2008).  Other studies have demonstrated similar results, 
describing considerable improvements in depressive symptoms with ropinirole 
(Buchwald et al., 2007). Published data of the effect of rasagiline on depressive 
symptoms in PD patients is controversial. A post-hoc analysis of the data from the 
ADAGIO study in drug naïve PD patients showed that the add-on therapy with 
rasagiline (1 or 2 mg per day) had a beneficial effect on depression in PD patients on 
antidepressive medication (Smith et al., 2015). However, other studies do not confirm 
this positive finding (Barone et al., 2015). A multicenter, open-label, prospective, 
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observational 6-month study comparing the effect of apomorphine to IJLI on NMS, 
motor symptoms and quality of life indicated that both advanced therapies improve 
the NMSS domain mood/apathy with a superiority observed with apomorphine 
(Martinez-Martin et al., 2015). 
Furthermore, omega-3 fatty-acid supplementation has been reported to be useful for 
depressive symptoms in PD (da Silva et al., 2008). 
Deep brain stimulation with subthalamic nucleus (STN) or internal globus pallidus  
(GPi) stimulation showed a short-term improvement in depression (mainly class I and 
II data) and anxiety (class I data) with a waning in effect over the longer term(Couto 
et al., 2014). Differences between both targets could not be elucidated. 
 
In conclusion, depression and anxiety is integral to PD and can occur as part of the 
disease process or non-motor fluctuations. Management therefore needs to address the 
underlying cause, however, robust evidence based for good anti-depressants anti-
anxiolytics including NSRIs, SSRIs TCA, dopamine agonists and other agents is still 
lacking. At this moment in time, current data does not indicate towards one specific 
class of antidepressants when compared with a placebo. 
 
 
 
 
Autonomic  
Orthostatic hypotension  
Orthostatic hypotension (OH) is a clinical sign defined by a drop of systolic blood 
pressure (SBP) of at least 20 mmHg or diastolic blood pressure of at least 10 mmHg 
	12		
within 3 minutes after assuming a standing position. It may be asymptomatic or 
accompanied with orthostatic symptoms such as dizziness, lightheadedness, or 
syncope (Freeman et al., 2011). Prevalence of OH in PD is estimated to be around 30-
40% (Velseboer et al., 2011). OH prevalence increases with disease duration (Rocchi 
et al., 2015) and might be worsened by dopaminergic therapy in which case a dose 
reduction in refractory cases should be considered (Park and Stacy, 2011). 
The management of neurogenic OH (nOH) in PD is complex and requires patient 
education to optimally control symptoms that have functional impact on activities of 
daily living. Recommended practical values are a standing SBP ≥ 90 mmHg and a 
supine SBP ≤ 180 mmHg (Low and Tomalia, 2015). 
Non-pharmacological therapies are first line interventions. Increased salt intake, 
increased water intake, and compression stockings ameliorate orthostatic symptoms 
(Wu and Hohler, 2015). Drinking caffeine-rich beverages, practice regular exercise, 
and avoiding warm weather and hot baths might provide some benefit as well for 
some patients (Figuerosa et al., 2010, Sanchez-Ferro et al., 2013) 
There is an increasing number of pharmacological therapies available and these are 
often administered in conjunction with non-pharmacologic interventions. 
Fludrocortisone, midodrine, droxidopa, domperidone, pyridostigmine and yohimbine 
have been used with different profiles of efficacy, mechanisms of action and side 
effects (Wu and Hohler, 2015). Domperidone might help OH, however owing to 
cardiovascular risks this cannot be routinely recommended. Furthermore, drugs 
therapies vary between countries.  
 
Droxidopa (L-threo-dihydroxyphenylserine, L-DOPS) is a synthetic catechol-amino 
acid that is converted to norepinephrine by the enzyme dopa-decarboxylase. 
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Droxidopa has been approved by the Food and Drug Administration (FDA) in the US 
for use in neurogenic OH (nOH) in PD since 2014, partly based on results from 
several studies including multicenter double-blind randomized placebo-controlled 
studies(Kaufmann et al., 2014, Biaggioni et al., 2015, Hauser et al., 2015). However, 
not all studies confirmed the beneficial effect of droxidopa and further investigations 
are needed (Schrag et al., 2015). 
 
Only a few studies assessed the effect of DBS on autonomous symptoms including 
OH problems in PD patients. In a small study involving 14 PD patients, a decrease in 
blood pressure could be observed in the ‘off’ compared to the ‘on’ state, suggesting a 
positive influence of bilateral subthalamic nucleus stimulation on blood pressure 
(Stemper et al., 2006) and the positive effect on orthostatic hypotension was 
confirmed by other groups (Kurtis et al, 2017).  
In contrast, other studies could not find major effects of DBS on cardiovascular 
autonomic nervous system functions (Ludwig et al., 2007, Lipp et al., 2005, Erola et 
al., 2006). Whether this potential positive effect is secondary to the reduction of oral 
medication after surgery or is a direct result of stimulating  central pathways, remains 
to be clarified and needs further investigation. 
 
In summary, OH occurs more commonly in PD than initially realized and recently 
droxidopa therapy has been shown to be effective, although not all research has 
confirmed this. While conventional and supportive therapies are effective, large scale 
control studies with new investigational products are required. 
 
Urinary dysfunction 
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Lower urinary tract symptoms (LUTS) and dysfunction are commonly reported to 
play a key role in the quality of life of PD patients, however randomized clinical trials 
addressing urinary dysfunction are currently lacking. LUTS are composed of two 
major categories: storage symptoms (e.g. urgency, frequency, nocturia, and 
incontinence) and voiding symptoms (e.g. hesitancy, interrupted or poor stream, and 
double voiding), and both are reported to occur in PD (Sakakibara et al., 2014). 
Storage symptoms are thought to be related to detrusor overactivity and voiding 
symptoms may result from bladder hypoactivity or an obstruction in the lower urinary 
tract. However, nocturia is one of the most reported symptoms followed by frequency 
(McDonald et al., 2016). 
 
When addressing urinary dysfunction, it is important to establish if the symptoms are 
related to fluctuations in which case adjustment of dopaminergic medication can be 
considered. However, the role of dopaminergic medication in the management of 
LUTS is unclear, with most studies using urodynamic studies to date showing 
conflicting results (McDonald et al., 2016, Sakakibara et al., 2016). At the same time, 
even though most bladder dysfunction is related to PD itself, it is important to check 
for common bladder diseases as recently summarized by Sakakibara et al (Sakakibara 
et al., 2016). Male and female patients over 50 years-old should be investigated for 
benign prostatic enlargement and stress-induced urinary incontinence, respectively 
(Sakakibara et al., 2016). 
Anti-muscarinics are used routinely in clinical practice to treat overactive bladder 
with Oxybutynin being the most investigated one. 
Solifenacine, darfenacin and trospium were approved by the FDA together with two 
further antimuscarinic agents darfenacin and trospium in 2004 for its use in overactive 
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bladder (Hesch, 2007). A recent study by the Parkinson Study Group with a 
randomized, placebo-controlled 3-site setting measuring the mean number of 
micturitions per 24h as a primary outcome, showed no significant improvement 
among the treated group, but showed a significant reduction in the number of 
incontinence and nocturia episodes (Zesiewicz et al., 2015). Furthermore, Propiverine 
and Tolterodine were studied (Sakakibara et al., 2016). 
Intravesical botulinum toxin injections have been reported to be successful in treating 
hyperactive bladder dysfunction (Kulaksizoglu and Parman, 2010; Giannantoni et al., 
2011). 
Newer treatment options currently being investigated for bladder dysfunction include; 
a beta-3 adrenergic agonist such as Mirabegron, DBS, as well as posterior tibial nerve 
stimulation (PTNS)(Schrag et al., 2015) (Sakakibara et al., 2016). 
 
In conclusion, urinary dysfunction may complicate PD from an early stage and might 
even be a prodromal sign. Management of urinary dysfunction remains a key unmet 
need although recent clinical trials with Solifenacine seem promising. 
 
 
 
Gastrointestinal dysfunction 
Gastrointestinal dysfunction plays a key role in PD with constipation being the most 
common symptom (Rossi et al., 2015).  In the literature, constipation is characterized 
as less than three bowel movements a week or having to strain to pass a stool 
(Chaudhuri et al., 2006b). Limited data is published on the management of 
constipation in PD patients. In the literature constipation in PD is sometimes divided 
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into two types; constipation due to slow colonic transit and/or constipation due to 
defecatory dysfunction , which is often related to pelvic floor dyssynergia (Rossi et 
al., 2015).  
In relation to the first form of constipation, after exclusion of secondary causes, 
lifestyle changes are among the first-line recommendation as they can have a 
significant positive impact. These include an increase in the amount of fibre and water 
intake as well as physical activity (Barboza et al., 2015, Rossi et al., 2015).  In case 
these non-pharmacological strategies are not successful, bulk forming laxatives such 
as psyllium and osmotic laxatives including polyethylene glycol (PEG, macrogol) 
have been shown useful to treat constipation.  as Additionally,  the FDA approved 
chloride channel activator called lubiprostine and similarly the guanylate cyclase C 
receptor peptide called linaclotide have shown useful to treat constipation. Also, the 
serotonin 5-HT4 receptor agonist mosaprode has been studied alongside elobixibat 
and ileal sodium/bile acid co-transoprter	(Barboza	et	al.,	2015).   
On the other hand, levodopa or apomorphine injection, botulinum toxin injections into 
the puborectalis muscle, and non-pharmacological interventions, like 
biofeedback therapy or functional magnetic stimulation have been reported to 
improve the defecatory dysfunction related constipation (Rossi et al., 2015). 
Another development has addressed the effect of ghrelin receptor agonist (HM01) in 
rats, in vitro as well as in vivo and found promising results, however, these need 
further investigation (Karasawa et al., 2014).  
 
In conclusion, gastrointestinal dysfunction are common non-motor features in PD 
with constipation being the most frequent one. Exclusion of secondary causes is 
important and non-pharmacological treatment strategies can often offer a considerable 
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improvement. Several pharmacological treatments such as laxatives are routinely used 
in clinical practice while new drugs are currently under development.  
 
The possible role of nutrition and Parkinson’s disease  
While historically relegated to the symptomatic management of dysphagia, 
constipation and interactions between dietary protein and levodopa, it is now evident 
the topic of nutrition in PD is more complex than once thought. Epidemiological 
studies suggests coffee, tea, dark berries, a plant-based diet and dairy avoidance 
decrease PD incidence (Qi and Li, 2014, Gao et al., 2012, Jiang et al., 2014, Gao et 
al., 2007), and studies are underway to evaluate whether these variables are associated 
with PD progression (Mischley LK, 2015). Early involvement of the gastrointestinal 
tract is supported by the finding that constipation and α-synuclein aggregation are 
observed in the salivary glands and intestinal mucosa over a decade prior to the onset 
of PD motor symptoms (Adams-Carr et al., 2016, Mukherjee et al., 2016). Recently, 
of alterations in the intestinal microbiome have been described (Scheperjans, 2016) 
and a dietary Lactobacillus supplement was shown to improve bowel health (Cassani 
et al., 2011). Beyond diet, perturbations in essential metabolites have also been 
demonstrated in PD; patients are more likely be deficient in glutathione (Zeevalk et 
al., 2008), coenzyme Q10 (Mischley et al., 2012), lithium (Mischley, 2013),and folic 
acid, the latter attributable to a levodopa side effect (Paul and Borah, 2016). Not all 
drug-nutrient interactions are negative, as several studies suggest cytidine diphosphate 
choline has a levodopa-sparing effect (Cubells and Hernando, 1988). It is unclear 
whether a subset of PD symptoms are manifestations of nutritional deficiency 
symptoms or whether depletion of nutrients is associated with disease progression 
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(Mischley, 2014). To date, no guidelines exist for the screening, evaluation, and 
management of nutrition in PD.  
 
Non-motor subtype specific treatment in Parkinson’s disease? 
NMS are a major determinant of quality of life and caregiver stress. In spite the 
evidence based for treatment on NMS, in particular level I evidence remains scare. 
Most clinical trials still focus dominantly on the motor symptoms in spite of the 
availability of holistic NM measurements. However, the recognition of specific NMS 
subtypes is likely to generate trials focused on subtype specific medicine and more 
individualized treatment in future. Such strategy will enhance the quality of life of 
many PD patients with the high non-motor burden in future. 
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